[A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
The aim of this paper was to show the validity of programmed treatment of chronic myeloid leukemia (CML) patients regarding the risk group. In a group of low CML risk monochemotherapy (myelosan or hydroxyurea) was applied. In a group of moderate or high CML risk cytostatic therapy was performed in two variants: as monotherapy and polychemotherapy. Of 112 patients with CML, 50 received cytostatics plus long-term course of interferon-alpha. The combined treatment was well tolerated.
Khoroshko
N D
ND
Turkina
A G
AG
Zhuravlev
V S
VS
Sokolova
M A
MA
Mikhaĭlova
I N
IN
Zakharova
A V
AV
Domracheva
E V
EV
Semenova
E A
EA
D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007370:Interferon Type I / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D012307:Risk Factors; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D007370:Interferon Type I; D011994:Recombinant Proteins; D002066:Busulfan; D006918:Hydroxyurea